PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2016

MG53 permeates through blood-brain barrier to protect ischemic brain injury.

Mixed / Ischaemia-reperfusion

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 26967557 ↗2016Reported benefit

MG53 permeates through blood-brain barrier to protect ischemic brain injury.

MixedIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-Dawley rats; tPA-MG53 transgenic mice with littermate wild-type controlsn = n=7 per group for rat infarct size and neurological score;…Intravenous, via left external jugular vein catheter in rats, tail vein in the general protocol3 mg/kg body weight (single dose); 60 micrograms/ml for 2 h…30 min before ischaemia, immediately after ischaemia, or 1, 2, 4 or 6 h after r…

Model: Transient middle cerebral artery occlusion, 60 min occlusion followed by reperfusion for 24 h

A single intravenous dose of rhMG53 at 3 mg/kg given 30 min before ischaemia or up to 4 h after reperfusion reduced infarct area, improved Zea-Longa scores at 24 h, reduced TUNEL positivity and caspase-3 activation, and restored Akt and GSK3-beta phosphorylation. Benefit was lost when dosing was de…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.